RubrYc Therapeutics Announces a Research Collaboration and License Option Agreement With Zai Labs

SAN CARLOS, Calif.–(BUSINESS WIRE)–Apr. 14, 2021 RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies, today announced that it has entered into a research collaboration and license option agreement with Zai Labs, Inc. for the use of RubrYc’s Meso-scale Engineered Molecules (MEMs) platform, to identify monoclonal antibodies with enhanced biological function for an […]

LintonPharm Announces Authorization from China Health Authority (NMPA) to Proceed with a Phase 1/2 Trial Evaluating Catumaxomab for the treatment of Non-Muscle Invasive Bladder Cancer

GUANGZHOU, China–(BUSINESS WIRE)–Apr. 13, 2021 LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that China’s health authority, National Medical Products Administration (NMPA) authorized the company to proceed with a Phase 1/2 clinical trial (clinicaltrials.gov: NCT04799847) evaluating the safety and […]

Takeda Begins Regulatory Submissions for Dengue Vaccine Candidate in EU and Dengue-Endemic Countries

European Medicines Agency to Conduct First-Ever Parallel Assessment of a Medicinal Product, Takeda’s Dengue Vaccine Candidate (TAK-003), for use in the EU; Countries Outside of the EU through the EU-M4all (Previously Article 58) Procedure − Takeda Intends to Submit Regulatory Filings in Argentina, Brazil, Colombia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka and Thailand During 2021 − TAK-003 […]

Premas Biotech and Oramed Announce Oral COVID-19 Vaccine Candidate That Produces Antibodies After a Single Dose

Far reaching implications for ease of widescale distribution and administration anytime, anywhere Better candidate for protection against COVID-19 variants due to triple antigen targeting Oravax Medical Inc. established to accelerate vaccine’s path to market Clinical trials expected to commence Q2 2021 GURUGRAM, India–(BUSINESS WIRE)–Mar. 22, 2021 Premas Biotech, a developer of novel biotherapeutic and vaccine […]

Illuminating the Heroes of Rare Diseases

Australian health advocates join global movement to raise awareness for Rare Disease Day – Sunday 28 February SYDNEY–(BUSINESS WIRE)–Feb. 26, 2021 With a mission of empowering the rare disease community, Illumina has today partnered with medical researchers and families to highlight the importance of genomic sequencing and to shine the spotlight on the 300 million […]

Aptorum Group Announces Submission of Clinical Trial Application for ALS-4 an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)

NEW YORK & LONDON & PARIS–(BUSINESS WIRE)–Dec. 21, 2020 Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies for the treatment of a variety of medical conditions including infectious diseases, announced that the company, through its wholly owned subsidiary Aptorum International Limited, has […]

New Studies Conclude Xlear Kills and/or Deactivates SARS-CoV-2

MIAMI–(BUSINESS WIRE)–Nov. 30, 2020 New in vitro studies, led by renowned authority on respiratory diseases, conclude Xlear nasal spray is “an effective…and replicable means to deactivate SARS-CoV-2…to an undetectable amount of infectious virus.” This conclusion is “validated by two independent sets of experiments, performed by different labs, on different viral strains…” The Virucidal studies were […]

Humanigen Australia Proprietary Limited Established to Facilitate Asia-Pacific Growth Plans

New Humanigen entity in Australia creates focused opportunity for partnering, regional clinical trials and market access Structure allows for attractive financial incentives supported by the Australian government BURLINGAME, Calif.–(BUSINESS WIRE)–Nov. 24, 2020 Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its […]

NTHU Researchers Discover New Gastric Cancer Biomarkers for Tailored Therapy

HSINCHU, Taiwan–(BUSINESS WIRE)–Nov. 14, 2020 A research team led by Professor Wang Wen-ching of the Institute of Molecular and Cellular Biology, National Tsing Hua University (NTHU) has exploited the power of big data to identify two key biomarkers contributing to the proliferation and metastasis of gastric (stomach) cancer. Using the US Food and Drug Administration […]

Mevion Partners with Hermes Advanced Therapy Systems to Expand Reach in Asia

LITTLETON, Mass.–(BUSINESS WIRE)–Oct. 19, 2020 Mevion Medical Systems is pleased to announce it has entered a partnership agreement with Hermes Advanced Therapy Systems Corp. (HATS) for the distribution of the MEVION S250i Proton Therapy System® in Taiwan and Southeast Asia, including Malaysia, Thailand, and Singapore. As a subsidiary of Hermes-Epitek Corp., a trusted provider of […]